Neuroimaging studies of GABA in schizophrenia: a systematic review with meta-analysis.

Data from animal models and from postmortem studies suggest that schizophrenia is associated with brain GABAergic dysfunction. The extent to which this is reflected in data from in vivo studies of GABA function in schizophrenia is unclear. The Medline database was searched to identify articles published until 21 October 2016. The search terms included GABA, proton magnetic resonance spectroscopy (1H-MRS), positron emission tomography (PET), single photon emission computed tomography (SPECT), schizophrenia and psychosis. Sixteen GABA 1H-MRS studies (538 controls, 526 patients) and seven PET/SPECT studies of GABAA/benzodiazepine receptor (GABAA/BZR) availability (118 controls, 113 patients) were identified. Meta-analyses of 1H-MRS GABA in the medial prefrontal cortex (mPFC), parietal/occipital cortex (POC) and striatum did not show significant group differences (mFC: g=-0.3, 409 patients, 495 controls, 95% confidence interval (CI): -0.6 to 0.1; POC: g=-0.3, 139 patients, 111 controls, 95% CI: -0.9 to 0.3; striatum: g=-0.004, 123 patients, 95 controls, 95% CI: -0.7 to 0.7). Heterogeneity across studies was high (I2>50%), and this was not explained by subsequent moderator or meta-regression analyses. There were insufficient PET/SPECT receptor availability studies for meta-analyses, but a systematic review did not suggest replicable group differences in regional GABAA/BZR availability. The current literature does not reveal consistent alterations in in vivo GABA neuroimaging measures in schizophrenia, as might be hypothesized from animal models and postmortem data. The analysis highlights the need for further GABA neuroimaging studies with improved methodology and addressing potential sources of heterogeneity.

Introduction

One of the most consistent findings from postmortem studies in schizophrenia is a reduction in the GABA-synthesizing enzyme, GAD67 mRNA and protein.[1, 2, 3] Expression of GAD67 is activity regulated[4, 5] and GAD67 is responsible for over 90% of all (cytosolic) GABA production.[6] In contrast to GAD67, inconsistent findings in schizophrenia are reported for the GAD65 isoform,[7, 8, 9, 10] which is involved in vesicular, synaptic GABA production during intense periods of neural activity.[11, 12] The potential effects of a reduction in GAD67 on cortical excitatory/inhibitory networks is a key component in some neurobiological models of schizophrenia.[13] In particular, GABA dysfunction is thought to lead to the disinhibition of glutamatergic pyramidal neurons and a loss of synchronous cortical activity.[14, 15] Postmortem studies also suggest that schizophrenia is associated with dysfunctional GABA signalling at the postsynaptic receptor level. Receptor autoradiography using 3H-muscimol, an agonist at the GABA binding site on the GABAA/benzodiazepine receptor (GABAA/BZR) complex, has consistently shown an increase in binding density in the prefrontal, cingulate and temporal cortices and caudate nucleus.[16, 17, 18, 19, 20, 21, 22] In contrast, density of binding to the BZ binding site of the GABAA/BZR complex has been found unaltered, increased or decreased postmortem.[22, 23, 24, 25, 26, 27] Postmortem investigations of GABAA α subunit expression have found reductions in α1 (refs 28, 29) and increases in α2 (refs 29, 30) expression in schizophrenia, but inconsistent results for the α5 subunit.[29, 31, 32]

GABA function in schizophrenia can be assessed in vivo using neuroimaging techniques. Proton magnetic resonance spectroscopy (1H-MRS) optimized for GABA detection can measure GABA concentrations within a voxel of interest. This approach measures total (intracellular and extracellular) GABA and macromolecules (denoted GABA+) across all tissue content in a relatively large voxel. An alternative neuroimaging approach is to use positron emission tomography (PET) or single photon emission computed tomography (SPECT) in conjunction with specific radiotracers that bind to GABA or BZ receptors.[33] However, all the PET/SPECT radiotracers currently available for human use bind to the BZ rather than to the GABAA site of GABAA/BZ receptors. The PET/SPECT radiotracers iomazenil and flumazenil have limited subunit selectivity, binding GABAA/BZ receptors containing α1, α2, α3 and α6 subunits, whereas Ro15-4513 has more selectivity for α1 and α5.[34]

Neuroimaging of GABA function is potentially important because several hypotheses around the role of GABA dysfunction in schizophrenia can only be tested in vivo. Evidence that GABA dysfunction has a role in the pathophysiology of schizophrenia has also led to interest in the therapeutic potential of pharmacological compounds that act on GABA function, and data from animal studies suggest that administration of benzodiazepines can prevent the development of neuroanatomical and neurophysiological abnormalities associated with schizophrenia.[35, 36]

Although there have been several neuroimaging studies of GABA in schizophrenia, the nature of GABAergic abnormalities in schizophrenia in vivo remains unclear. The present study aims to address this issue by conducting a systematic review and a meta-analysis of 1H-MRS and PET/SPECT studies of GABA in schizophrenia. In our primary analyses as well as studies of patients with schizophrenia, we included studies of subjects at high clinical or genetic risk for the disorder, as GABAergic dysfunction may be a ‘trait’ characteristic, arising through the influences of genetic variation during development.[37] The potential influence of clinical subgroups,[38, 39] medication status,[38, 40] symptom severity,[38, 40, 41] age[42, 43] and gender[44] were investigated using subsequent moderator analyses and meta-regression.

Materials and methods

Study selection

The meta-analysis and systematic review was performed in accordance with the guidelines of the PRISMA group.[45] The Medline electronic database was searched to identify journal articles published from 1 January 1950 until 21 October 2016, using the following MeSH and freeform search terms: (‘GABA’) AND (‘MRS’ OR ‘spectroscopy’ OR ‘positron emission tomography’ OR ‘single photon emission tomography’ OR ‘single photon emission computed tomography’ OR ‘PET’ OR ‘SPET’ OR ‘SPECT’) AND (‘schizophrenia’ OR ‘psychosis’ OR ‘schizophreniform’ OR ‘psychosis risk’). Reference lists of the returned articles were hand searched for further relevant publications. Two authors independently performed the searches and identified articles for inclusion (AE and DF).

Inclusion required that articles were published in peer-reviewed journals in English or English translation. Inclusion also required that articles reported GABA measures in vivo, in a group with clinical diagnosis of schizophrenia, schizoaffective disorder or first episode psychosis, or a group at clinical or genetic risk for schizophrenia, compared with a healthy volunteer (control) group. 1H-MRS studies were excluded if they reported the GABA signal only as the combined signal with glutamate (Glx). PET/SPECT studies were excluded if they investigated translocator protein, which mediates various mitochondrial functions and was previously described as the peripheral benzodiazepine receptor.[46] Where articles reported overlapping samples, only data from the article reporting the largest sample was included.

Outcome measures

The primary outcome measure was the control and patient mean and standard deviation (s.d.) 1H-MRS GABA+ concentration in each voxel, or GABAA/BZR availability in each region of interest. Where these values were not reported in the published article, the authors were contacted or values were estimated from figures using a freely available ruler for Mac OS X (http://www.pascal.com/software/freeruler/). Where values were reported in each hemisphere separately, the mean of these values was calculated. For 1H-MRS studies, due to partially overlapping voxel locations and to provide sufficient data for meta-analysis, data were combined into the medial frontal cortex (mFC), parietal and occipital cortices and striatum. All the variables were extracted independently by two authors (AE and DF) and cross-checked for accuracy.

Meta-analysis

Inclusion in the meta-analyses required availability of data in a given brain region from five or more studies.[47] Where there were insufficient data for meta-analysis, the findings were summarized. Where articles included more than one patient or control group, these groups were entered separately in the analyses. For each variable, the effect size statistic Hedges’ g was calculated. Hedges’ g is the Cohen’s effect size incorporating a correction for bias from small sample sizes.[48]

The meta-analysis for each variable was performed using STATA/IC, version 14, using the METAN command (StataCorp LP, College Station, TX, USA). A random-effects inverse-weighted variance model[49] was used to calculate the pooled effect size to adjust for study heterogeneity. Significance was assessed using two-sided 95% confidence intervals.

Heterogeneity was measured using the I2 value, which indicates the percentage variance due to heterogeneity between studies compared with chance.[50] Where I2 values indicated substantial heterogeneity (I2>50%), potential sources of heterogeneity were investigated by using sensitivity analysis to assess potential influences of single studies, and Egger’s test[51] to investigate potential publication bias.

Moderator analyses

Potential influences of study characteristics were investigated using moderator analyses. Subgroup analyses investigated the following dichotomous characteristics of data sets: (1) clinical category of subjects (first episode psychosis or schizophrenia patients versus clinical risk or genetic risk groups); (2) explicitly stated absence of GABAergic (benzodiazepine or anticonvulsant) medication at the time of scanning; (3) presence (in >90% of the sample) or absence (in 100% of the sample) of antipsychotic medication at the time of imaging. For mFC GABA 1H-MRS studies, subgroup analyses additionally investigated potential influences of mFC voxel location (Figure 1).

Figure 1

Voxel locations in medial frontal cortex GABA 1H-MRS studies. Numbers provide effect sizes (Hedge’s g) for the difference in 1H-MRS GABA level between patients and control participants for each study. Negative effect sizes indicate lower GABA in patients; positive effect sizes indicate lower GABA in controls. Subgroup membership was defined by voxel locations primarily in the Brodmann Areas (BA) BA4 and BA24 (posterior medial frontal cortex), BA24 and BA32 (medial prefrontal cortex) or BA24 and BA11 (ventromedial prefrontal cortex). 1H-MRS, proton magnetic resonance spectroscopy.

Meta-regressions were conducted to explore potential influences of continuous variables relating to patient characteristics (age, percentage male in sample, illness duration, Positive and Negative Syndrome Scale total score), voxel grey matter content and publication year on GABA measures. Symptoms rated using the BPRS were converted to Positive and Negative Syndrome Scale scores using the established conversion scale of Leucht et al.[52] Meta-regression analyses were performed in STATA/IC version 14 using the METAREG command, with Hedges’ g as the outcome variable. To reduce the likelihood of chance findings, both subgroup analyses and meta-regressions required a minimum of five data sets. In all cases, the threshold for statistical significance was P<0.05.

Study quality and methodological characteristics

The methodological characteristics of 1H-MRS and PET/SPECT studies are summarized in Supplementary Tables 1 and 2, respectively. Although there are no established criteria for formal quality assessment of 1H-MRS and PET/SPECT studies, key factors that may impact on data quality are discussed in the Supplementary Information.

Results

1H-MRS studies

Nineteen articles describing 1H-MRS studies of GABA+ in schizophrenia were identified (Supplementary Figure 1). Of these, the article by Chen et al.[53] was excluded due to partial overlap with the larger sample reported in Kegeles et al.[40] Similarly, the article by Rowland et al.[54] was excluded due to overlap with the larger sample reported in Rowland et al.[43] Data from a single study were reported across two articles[55, 56] from which data extraction was combined. The clinical characteristics of the 1H-MRS samples are provided in Table 1. Data used to calculate effect sizes are available in Supplementary Table 1. The methodological characteristics are provided in Supplementary Table 2.

Table 1

1H-MRS GABA data sets: clinical characteristics of the samples

Region	First author (reference)	Year	Patient group	g	Sample size		SCZ %M	SCZ age mean	%AP	%BZ	PANSS	DOI
					C	SCZ
mFC	Goto[55, 56]	2009	FEP	−0.2	18	18	50	29	100	NR	68	0.5
	Öngür[57]	2010	SCZ	0.5	19	21	67	39	95	76	51	21
	Tayoshi[58]	2010	SCZ	−0.3	29	38	53	34	100	42	51	21
	Kegeles[40]	2012	SCZ unmed	0.7	11	16	69	32	0	19	71	7
	Kegeles[40]	2012	SCZ med	0.2	11	16	69	32	100	19	57	9
	Rowland[42]	2013	SCZ young	0.0	10	11	82	30	100	0	63	7.7
	Rowland[42]	2013	SCZ old	−1.0	10	10	70	51	100	0	57	25.5
	Marsman[59]	2014	SCZ	−0.8	19	13	76	28	100	35	53	6.5
	De la Fuente Sandoval[41]	2015	CHR	0.7	24	23	65	21	0	0	NR	—
	Brandt[60]	2016	SCZ	0.3	24	24	79	38	100	17	NR	NR
	Marenco[38]	2016	Siblings	−0.7	61.3	31	55	30	0	0	NR	—
	Marenco[38]	2016	SCZ unmed	−0.4	61.3	25	72	28	0	0	NR	6.0
	Marenco[38]	2016	SCZ med	−0.3	61.3	70	71	31	100	36	NR	9.5
	Menschikov[61]	2016	CHR	−4.1	26	21	100	NR	NR	NR	NR	—
	Rowland[43]	2016	SCZ young	0.0	40	29	69	26	93	0	NR	5.6
	Rowland[43]	2016	SCZ old	−0.7	37	31	61	48	90	0	NR	24
	Yang[62]	2016	FEP	0.8	23	22	41	26	0	NR	69	1.6
POC	Goto[55, 56]	2009	FEP	0.2	18	18	50	29	100	NR	68	0.5
	Öngür[57]	2010	SCZ	0.4	19	21	67	39	95	76	51	21
	Yoon[63]	2010	FEP/SCZ	−2.6	13	13	85	28	62	NR	73	NR
	Kelemen[64]	2013	FEP	−0.7	20	28	64	25	0	0	88	0.8
	Marsman[59]	2014	SCZ	0.3	19	15	76	28	100	35	53	6.5
	Thakkar[39]	2016	Sibling	0.0	12	23	53	31	0	0	NR	—
	Thakkar[39]	2016	SCZ	−0.5	12	21	71	36	100	24	49	14
Striatum	Goto[55, 56]	2009	FEP	−0.8	18	18	50	29	100	NR	68	0.5
	Tayoshi[58]	2010	SCZ	−0.2	29	38	53	34	100	42	51	21
	De la Fuente Sandoval[41]	2015	CHR	1.3	24	23	65	21	0	0	NR	—
	Thakkar[39]	2016	Sibling	−0.3	12	23	53	31	0	0	NR	—
	Thakkar[39]	2016	SCZ	−0.1	12	21	71	36	100	24	49	14
dlPFC	Kegeles[40]	2012	SCZ unmed	−0.1	11	16	69	32	0	19	71	7
dlPFC	Kegeles[40]	2012	SCZ med	−0.4	11	16	69	32	100	19	57	9
Hippocampus	Stan[65]	2015	SCZ	−0.2	16	18	78	42	61	28	NR	NR
CSO	Rowland[42]	2013	SCZ younger	0.2	10	11	82	30	100	0	63	7.7
CSO	Rowland[42]	2013	SCZ older	−0.7	10	10	70	51	1000	0	57	25.5

Abbreviations: %AP, percentage of SCZ group currently taking antipsychotic medication; %BZ, percentage of SCZ group currently taking benzodiazepine or anticonvulsant medication; C, control; CHR, clinical high risk; CSO, centrum semiovale; dlPFC, dorsolateral prefrontal cortex; DOI, mean duration of illness in years; FEP, first episode psychosis; g, Hedge’s g effect size; %M, percentage of male in the SCZ sample; mFC, medial frontal cortex area; NR, not reported; PANSS, Positive and Negative Syndrome Scale mean total symptom score; POC, parietal/occipital cortex; SCZ, schizophrenia or schizophreniform disorder; sibling, healthy siblings of patients with SCZ. Age is expressed in years (mean).

Medial frontal cortex

Twelve articles[38, 40, 41, 42, 43, 55, 57, 58, 59, 60, 61, 62] involved 17 data sets for GABA+ in the mFC, providing data from a total of 409 patients and 495 controls. Meta-analysis returned a summary effect size of g=−0.3, which was nonsignificant (95% confidence interval: −0.6 to 0.1, P=0.1, Figure 2a). The I2 value was 84%, indicating a significant (P<0.001) and considerable heterogeneity across data sets.[50] Visual inspection of the Forrest plot (Figure 2a) shows that one study[61] was clearly an outlier, and that of the remaining studies, approximately half reported higher GABA+ levels in patients than controls, while the other half reported the opposite. The recalculated summary effect size after removal of the outlying data set was g=−0.1, which was also nonsignificant (95% confidence interval: −0.4 to 0.2, P=0.5, I2=69%). Sensitivity analyses did not return significant results on any iteration, and the Eggers test did not suggest publication bias.

Figure 2

(a–d) Forest plots showing effect sizes (Hedge’s g) for 1H-MRS GABA studies in schizophrenia versus control. Error bars represent 95% confidence intervals. Black squares indicate data from clinical patient samples (FEP or SCZ) while white squares indicate data from CHR or sibling samples. CHR, clinical high risk; FEP, first episode psychosis; 1H-MRS, proton magnetic resonance spectroscopy; SCZ, schizophrenia or schizoaffective disorder; sibling, unaffected siblings of patients with schizophrenia; med, currently receiving antipsychotic medication; unmed, currently unmedicated with antipsychotics.

Available data sets permitted a series of subgroup analyses, which involved studies that (i) only included patients with a first episode of psychosis or schizophrenia (14 data sets[38, 40, 42, 43, 55, 57, 58, 59, 60, 62]); (ii) explicitly excluded patents taking benzodiazepine or anticonvulsant medication (eight data sets[38, 41, 42, 43]); (iii) included patients of whom >90% were being treated with antipsychotic medication (12 data sets[38, 40, 42, 43, 55, 57, 58, 60]); (iv) excluded subjects who had taken antipsychotic medication (five data sets[38, 40, 41, 62]); or (v) included only 1H-MRS voxels in the medial prefrontal area of the medial frontal cortex (Figure 1; 10 data sets[40, 41, 42, 43, 57, 59, 60]). All of these subgroup analyses returned nonsignificant summary effect sizes and I2 values >50%. Meta-regression did not reveal any significant relationships between mFC GABA+ and age, illness duration, symptom severity, percentage grey matter in the voxel or publication date. There was a significant association with percentage of males in the sample (17 observations, β=−0.04; t=−2.5; P=0.03), but this was driven by outlying values from one study that included only male subjects.[61] The effect was no longer significant when this study had been removed (β=−0.004; t=−0.4; P=0.7).

Parietal/occipital cortex

Meta-analysis of GABA+ in the parietal/occipital cortex included seven observations across six articles,[39, 55, 57, 59, 63, 64] providing data from a total of 139 patients and 111 controls. The summary effect size was nonsignificant (g=−0.3; 95% confidence interval: −0.9 to 0.3, P=0.3, I2=80% Figure 2b) with no indication of publication bias. Limiting the analysis to observations in first episode psychosis or schizophrenia (six observations[39, 55, 57, 59, 63, 64]) also returned nonsignificant summary effect sizes. There were insufficient data to investigate further subgroups. All meta-regression analyses were nonsignificant.

Striatum

Five data sets reported GABA+ in the striatum across four articles.[39, 41, 55, 58] The summary effect size was not significant (123 patients, 95 controls, g=−0.004; 95% confidence interval: −0.7 to 0.7, P<1.0, I2=82% Figure 2c), with no indication of publication bias. There were insufficient data for subgroup analyses and meta-regression returned nonsignificant findings.

Other brain regions

One study[40] examined GABA+ in the dorsolateral prefrontal cortex, one[42] examined GABA in the centrum semiovale and one[65] examined GABA+ in the left hippocampus (Table 1, Figure 2d). There were insufficient data for meta-analysis and no significant group differences in GABA+ were reported for these brain regions.

GABAA/BZR availability

Ten articles were initially identified, which reported GABAA/BZR availability in schizophrenia.[66, 67, 68, 69, 70, 71, 72, 73, 74, 75] Of these, three were excluded: one because it was a conference abstract rather than a paper,[66] one because it presented previously published data[69] and one because it did not include a control group[68] (Supplementary Figure 1). The clinical and methodological characteristics of the remaining seven articles[67, 70, 71, 72, 73, 74, 75] are provided in Table 2 and Supplementary Table 3, respectively. There were not sufficient ROI data to permit meta-analyses in any brain region. None of the individual ROI studies detected any significant differences in regional GABAA/BDZ receptor availability between patients and controls (Figure 3).[67, 71, 72, 75] Of the voxel-wise studies, one reported significantly lower GABAA/BZR availability in clinical high-risk subjects in the right caudate nucleus,[73] one reported lower GABAA/BDZ receptor availability in the left precentral gyrus in schizophrenia,[70] and one reported decreased GABAA/BDZ receptor availability in the subgenual cingulate cortex and left temporal pole, but increased GABAA/BDZ receptor availability in the right inferior occipital gyrus in schizophrenia.[74]

Table 2

PET/SPECT GABAA/BDZ receptor availability data sets: clinical characteristics of the samples

First author	Year	Patient group	Sample size		SCZ %M	SCZ age mean	%AP	%BZ	PANSS	DOI
			C	SCZ
Busatto[67]	1997	SCZ	12	15	93	29	60	NR	NR	6.5
Verhoeff[70]	1999	SCZ	24	25	100	41	80	0	NR	NR
Abi-Dargham[71]	1999	SCZ	16	16	100	44	69	0	NR	NR
Asai[72]	2008	SCZ	11	12	55	33	0	0	90.4	NR
Lee[74]	2013	SCZ	18	17	47	29	100	0	60.5	4.1
Kang[73]	2014	CHR	15	11	66	19	18	0	NR	—
Frankle[75]	2015	SCZ	22	17	65	28	0	NR	83	NR

Abbreviations: %AP, percentage of SCZ group currently taking antipsychotic medication; %BZ, percentage of SCZ group currently taking benzodiazepine or anticonvulsant medication; C, control; CHR, clinical high risk; DOI, mean duration of illness in years; %M, percentage of male in SCZ sample; NR, not reported; PANSS, Positive and Negative Syndrome Scale mean total symptom score; SCZ, schizophrenia. Age is expressed in years, mean; regional effect sizes are provided in Figure 2.

Figure 3

Illustration of effect sizes (Hedge’s g) for PET/SPECT studies of regional GABAA/BDZ receptor availability in schizophrenia versus control. Error bars represent 95% confidence intervals. ACC, anterior cingulate cortex; Cing. Ctx, cingulate cortex; dlPFC, dorsolateral prefrontal cortex; EC, entorhinal cortex; FC, frontal cortex; Hip, hippocampus; 1H-MRS, proton magnetic resonance spectroscopy; mFC, medial frontal cortex; mTC, medial temporal cortex; NAc, nucleus accumbens; OFC, orbitofrontal cortex; ParaHip, parahippocampus; PFC, prefrontal cortex; TC, temporal cortex. Studies reporting only voxel-wise analyses[70, 74] are excluded from the figure.

Frankle et al.[75] compared antipsychotic-naive and antipsychotic-exposed schizophrenia, finding elevated baseline GABAA/BZR availability in the antipsychotic-naive group across all brain regions investigated. Lee et al.[74] compared patients with schizophrenia currently taking aripiprazole or risperidone, and detected lower GABAA/BZR availability in the right medial, dorsolateral prefrontal, frontal polar and right premotor cortices in the aripiprazole group.

Three articles examined the relationship between GABAA/BZR availability and symptom severity.[70, 71, 75] None of these found significant associations. One article reported inverse relationships between positive symptoms and receptor binding in the medial temporal lobe, and between negative symptoms and binding in the medial frontal region.[67] Another article reported an inverse relationship between receptor binding in the prefrontal cortex and hippocampus and negative symptom severity.[72]

Frankle et al.[75] also examined the change in [11C] flumazenil VT following administration of the GABA transporter inhibitor tiagabine to increase GABA levels. This study detected no difference between the overall schizophrenia group compared with controls, but a smaller tiagabine-induced change in VT (GABA increase) in antipsychotic-naive patients, but not in antipsychotic-exposed patients, compared with controls.[75]

Discussion

The main finding of this article is that meta-analyses of 1H-MRS studies found no evidence for significantly altered GABA+ concentrations in patients with schizophrenia compared with healthy volunteers in the medial frontal cortex, parieto-occipital cortex or striatum. Analyses revealed a substantial level of heterogeneity across studies, which may relate to differences in patient samples and 1H-MRS methodological characteristics. Although there were insufficient studies of GABAA/BZR availability to perform meta-analysis, a systematic review of these studies found no consistent evidence for altered GABAA/BZR availability in schizophrenia.

To our knowledge, this is the first meta-analysis of 1H-MRS GABA studies in schizophrenia. Postmortem studies in schizophrenia find reductions in GAD67,[1, 2, 3] which is responsible for the majority of basal GABA synthesis in the cortex.[6] The 1H-MRS GABA signal may reflect the entire GABA content of the voxel (that is, intracellular and extracellular, and involved in metabolism or neurotransmission). Recent work argues that the 1H-MRS GABA signal predominantly relates to extracellular, extra-synaptic GABA providing tonic inhibitory tone, rather than GABA involved in phasic synaptic neurotransmission.[76, 77] Theoretically, the 1H-MRS GABA signal should therefore be sensitive to GAD67 reduction. However, our meta-analysis of in vivo 1H-MRS GABA studies in schizophrenia found that, although in cortical regions the summary effect sizes were consistent with lower GABA levels, these effect sizes were small and nonsignificant.

An absence of large, detectable differences in GABA concentrations in schizophrenia in vivo could reflect normalization by compensatory mechanisms at the cellular or network level,[15] and it is unknown whether GAD67 reduction in schizophrenia is primary, or secondary to other pathological mechanisms such as glutamatergic dysfunction.[78, 79] Furthermore, one limitation of 1H-MRS is that it measures total GABA concentrations within a relatively large voxel (mean 30 ml in the studies included in this article), which is determined a priori, and cannot discriminate between GABA levels in different cell types. This limits the application of 1H-MRS in addressing the cell- and network- specific GABA abnormalities hypothesized to occur in schizophrenia.[15]

The 1H-MRS meta-analysis also reflects several limitations in the currently available literature. Sixteen studies contributed to the meta-analysis, but there were relatively few investigations in each brain region, with non-overlapping voxel placements (for example in the mFC), variability between clinical samples and 1H-MRS methodological approaches and high heterogeneity. Meta-analysis revealed substantial variability in the findings across studies. For example, there were approximately equal numbers of studies reporting increases of GABA+ in the medial frontal cortex in schizophrenia as there were studies reporting reductions (Figure 2a), and all meta-analyses were associated with significant and high levels of heterogeneity. This may reflect between-study differences in patient samples, methodological approaches or relate to inconsistency in 1H-MRS GABA measurement. Regional brain GABA levels in schizophrenia may vary with the stage of the disorder, as has been reported in some individual studies,[38, 40, 42, 43] and appears to be evident for brain glutamate levels.[80] Our analysis was limited in that there were too few studies to perform meta-analyses of all patient subgroups in all regions. However, exclusion of data sets from ‘at risk’ participants (and thus restricting the analysis to patients with schizophrenia) did not change our findings. Similarly, the findings in the mFC remained nonsignificant and heterogeneous when the analysis was limited to either antipsychotic unmedicated or treated patients, or restricted to the prefrontal part of the medial frontal region. Moreover, meta-regression found no effect of duration of illness, participant age or symptom severity on GABA effect sizes. Nevertheless, there are several other clinical and methodological variables that might contribute to heterogeneity, such as the duration of treatment, time off medication or substance use, which we were not able to investigate in this meta-analysis. It is also possible that more complex relationships exist between two or more study variables on the GABA effect size, for example the location of GABA dysfunction within the mFC may vary with age or illness stage.

Owing to limited data availability, our meta-analysis did not account for the several methodological differences between studies that may have impacted on data quality. Differences in field strength, voxel size and acquisition times will translate to large between-study differences in the signal to noise ratio, and it was not possible to evaluate spectral quality in 7 of the 16 included articles (see Supplementary Information). Only two recent studies included methodology to isolate the GABA signal from macromolecule contamination,[39, 43] which is a key area for future methodological development. Therefore, while the meta-analyses did not indicate differences in regional GABA levels between patients and controls, this interpretation is limited pending publication of further individual studies. Future studies should directly compare different patient samples, maximize signal to noise ratio, address macromolecule contamination and include detailed and transparent reporting of spectral quality. On the basis of postmortem evidence, we suggest that key regions for investigation include the dorsolateral prefrontal cortex, anterior cingulate cortex and hippocampus.[3, 10, 17, 81, 82, 83]

Our systematic review of PET/SPECT studies examining GABAA/BZR availability also suggested an overall lack of evidence for differences in patients compared with controls, with no significant regional group differences in four out of seven studies.[67, 71, 72, 75] However, the three voxel-wise studies all reported lower GABAA/BZR availability in patients compared with controls, but there was no consistency across studies in the regions where these differences were detected.[70, 73, 74] All identified studies applied PET/SPECT radiotracers with affinity at the BZ site of the GABAA/BZR complex, and postmortem autoradiography studies of availability of BZ binding sites have also produced inconsistent results.[22, 23, 24, 25, 26, 27] This contrasts with reports of increases in availability of the GABA binding site on the GABAA/BZR in schizophrenia postmortem,[16, 17, 18, 19, 20, 21, 22] for which in vivo radiotracers are currently unavailable. A further consideration is that several PET/SPECT studies estimated regional GABAA/BZR availability relative to white matter,[67, 72, 73, 74] which may be confounded by the presence of white matter abnormalities in schizophrenia (see ref. 84).

In contrast to 1H-MRS, GABAA/BZR PET imaging may be able to measure changes in synaptic GABA concentrations. Frankle et al.[75] used this approach to examine the increase in GABA following administration of the presynaptic GABA reuptake inhibitor tiagabine. Although they found no difference between patients with schizophrenia and controls, when the analysis was restricted to the subgroup of patients that were antipsychotic-naive, the increase in GABA following tiagabine was significantly diminished. Tiagabine-induced increases in cortical GABA are not detectable using 1H-MRS,[85, 86] which is consistent with the view that the GABA 1H-MRS signal principally reflects nonsynaptic GABA. Pharmacologically induced alterations in synaptic GABA may be more sensitively imaged with [11C]Ro15-4513 PET, because it is a GABAA/BZR inverse agonist with greater selectivity for intra-synaptic receptors.[87] In the future, combination of this approach with 1H-MRS in the same subjects, and potentially during the same scanning session on combined PET-MR platforms, might investigate dysfunction of synaptic versus nonsynaptic GABA in schizophrenia.

Cluster analyses of postmortem data find that GABAergic deficits are not present in all schizophrenia patients, but characterize a patient subgroup of approximately 50% of the postmortem sample.[88, 89] This postmortem ‘Low GABA Marker’ (LGM) phenotype[89] does not readily relate to illness severity, psychoactive medication or substance use at the time of death.[88, 89] If a LGM subgroup could similarly be identified using in vivo biomarkers, this might lead to a stratified approach to treatments that address GABAergic dysfunction. It is possible that the heterogeneity in 1H-MRS studies may also reflect GABAergic subgroups of patients, either within- or between-study samples, which are again not readily identifiable by clinical variables. However, unlike postmortem studies, GABA imaging studies did not show consistently higher variability in GABA measurements in the patient compared with the control group (Supplementary Table 2). Combination of GABA 1H-MRS or GABA PET/SPECT with electroencephalogram gamma-band oscillations in schizophrenia,[53, 75, 90] which reflect on parvalbumin neuron activity,[91] may help determine whether such GABAergic subgroups of patients are identifiable in vivo.

In conclusion, at present, the neuroimaging literature suggests that brain GABA function, as indexed by 1H-MRS GABA concentrations and GABAA/BZR BZ site availability, does not provide a consistent pattern of alteration in schizophrenia. However, the total number of studies completed in this field is still relatively small, and most studies to date have involved small patient samples (typically 15–30 patients), and varying data quality (see Supplementary Information for discussion). It remains unclear if the absence of overall differences reflects confounding effects of age, stage of illness, medications or other unknown factors. Further studies using larger and more homogeneous samples may therefore be useful, as would studies directly comparing specific patient subgroups. Advances in both 1H-MRS and PET methodologies may reveal specific aspects of GABA dysfunction in vivo in schizophrenia within the next few years.